Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Oyanagi

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Anticancer Research|January 31, 2021
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR MutationHiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumabJun Oyanagi, Yasuhiro Koh, Koichi Sato, et al.
Cancers|June 2, 2021
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with NivolumabMio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, et al.
BMC Cancer|January 3, 2023
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trialSatoru Miura, Yasuhiro Koh, Koichi Azuma, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2019
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitorsYoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, et al.
Cancer Science|August 2, 2019
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancerYoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, et al.
Cancer Science|February 7, 2019
IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancerMizuho Sakahara, Takuya Okamoto, Jun Oyanagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Scientific Reports|March 12, 2021
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factorsMotohiro Izumi, Jun Oyanagi, Kenji Sawa, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2022
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitorsYuhei Harutani, Yuichi Ozawa, Eriko Murakami, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Anticancer Research|January 31, 2021
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR MutationHiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumabJun Oyanagi, Yasuhiro Koh, Koichi Sato, et al.
Cancers|June 2, 2021
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with NivolumabMio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, et al.
BMC Cancer|January 3, 2023
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trialSatoru Miura, Yasuhiro Koh, Koichi Azuma, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2019
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitorsYoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, et al.
Cancer Science|August 2, 2019
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancerYoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, et al.
Cancer Science|February 7, 2019
IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancerMizuho Sakahara, Takuya Okamoto, Jun Oyanagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Scientific Reports|March 12, 2021
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factorsMotohiro Izumi, Jun Oyanagi, Kenji Sawa, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2022
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitorsYuhei Harutani, Yuichi Ozawa, Eriko Murakami, et al.
Pageof 3